Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $290.90 | 11 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $91.80 | 4 | $0 (2024) |
| PBG PUERTO RICO LLC | $91.10 | 4 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $76.97 | 1 | $0 (2017) |
| Gilead Sciences, Inc. | $31.03 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44.14 | 2 | ABBVIE INC. ($25.00) |
| 2023 | $50.00 | 2 | ABBVIE INC. ($50.00) |
| 2021 | $102.99 | 5 | PBG PUERTO RICO LLC ($71.96) |
| 2017 | $93.77 | 2 | Merck Sharp & Dohme Corporation ($76.97) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VIROLOGY | ||||||
| 04/26/2024 | PBG PUERTO RICO LLC | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 09/20/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VIROLOGY | ||||||
| 04/04/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VIROLOGY | ||||||
| 12/17/2021 | PBG PUERTO RICO LLC | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/15/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.61 | General |
| 09/21/2021 | PBG PUERTO RICO LLC | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/12/2021 | PBG PUERTO RICO LLC | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 03/04/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.42 | General |
| 04/21/2017 | AbbVie, Inc. | Viekira (Drug) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: Virology | ||||||
| 01/28/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Food and Beverage | In-kind items and services | $76.97 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 20 | 43 | $3,901 | $2,882 |
| 2022 | 1 | 16 | 27 | $2,493 | $1,823 |
| 2021 | 3 | 38 | 59 | $6,070 | $3,647 |
| 2020 | 2 | 30 | 53 | $4,050 | $2,161 |
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 43 | $3,901 | $2,882 | 73.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 27 | $2,493 | $1,823 | 73.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 15 | 27 | $2,514 | $1,329 | 52.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 12 | 17 | $1,577 | $1,188 | 75.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 11 | 15 | $1,979 | $1,131 | 57.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 18 | 38 | $2,904 | $1,593 | 54.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 12 | 15 | $1,146 | $567.68 | 49.5% |
About Dr. Edwin Melendez Rios, M.D
Dr. Edwin Melendez Rios, M.D is a Gastroenterology healthcare provider based in Rio Piedras, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467556159.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edwin Melendez Rios, M.D has received a total of $290.90 in payments from pharmaceutical and medical device companies, with $44.14 received in 2024. These payments were reported across 11 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($290.90).
As a Medicare-enrolled provider, Melendez Rios has provided services to 104 Medicare beneficiaries, totaling 182 services with total Medicare billing of $10,514. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Rio Piedras, PR
- Active Since 09/12/2006
- Last Updated 09/13/2017
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1467556159
Products in Payments
- ZEPATIER (Drug) $76.97
- MAVYRET (Drug) $75.00
- XELJANZ (Drug) $71.96
- VELSIPITY (Drug) $19.14
- Viekira (Drug) $16.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Rio Piedras
Dr. Marcia Cruz-Correa, Md, MD
Gastroenterology — Payments: $23,060
Dr. Artemio Santiago-Molina, M.d, M.D
Gastroenterology — Payments: $2,782
Juan Tomasini, Md, MD
Gastroenterology — Payments: $1,699
Dr. Manuel Santini Santiago, M.d, M.D
Gastroenterology — Payments: $411.90